165 related articles for article (PubMed ID: 21559393)
1. Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
Winsel S; Sommer A; Eschenbrenner J; Mittelstaedt K; Klar U; Hammer S; Hoffmann J
PLoS One; 2011 Apr; 6(4):e19273. PubMed ID: 21559393
[TBL] [Abstract][Full Text] [Related]
2. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
[TBL] [Abstract][Full Text] [Related]
3. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo.
Strube A; Suominen MI; Rissanen JP; Mumberg D; Klar U; Halleen JM; Käkönen SM
Osteoporos Int; 2011 Nov; 22(11):2887-93. PubMed ID: 21104229
[TBL] [Abstract][Full Text] [Related]
5. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
[TBL] [Abstract][Full Text] [Related]
6. Gene expression and mitotic exit induced by microtubule-stabilizing drugs.
Chen JG; Yang CP; Cammer M; Horwitz SB
Cancer Res; 2003 Nov; 63(22):7891-9. PubMed ID: 14633718
[TBL] [Abstract][Full Text] [Related]
7. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
8. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.
Klar U; Hoffmann J; Giurescu M
Expert Opin Investig Drugs; 2008 Nov; 17(11):1735-48. PubMed ID: 18922109
[TBL] [Abstract][Full Text] [Related]
9. TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin.
Hinz TK; Kalkur R; Rabinovitch J; Hinkle W; Heasley LE
Mol Pharmacol; 2021 Aug; 100(2):144-154. PubMed ID: 34031188
[TBL] [Abstract][Full Text] [Related]
10. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U
Neuro Oncol; 2009 Apr; 11(2):158-66. PubMed ID: 18780814
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.
Eschenbrenner J; Winsel S; Hammer S; Sommer A; Mittelstaedt K; Drosch M; Klar U; Sachse C; Hannus M; Seidel M; Weiss B; Merz C; Siemeister G; Hoffmann J
Front Oncol; 2011; 1():44. PubMed ID: 22649765
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
13. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.
Arnold D; Voigt W; Kiewe P; Behrmann C; Lindemann S; Reif S; Wiesinger H; Giurescu M; Thiel E; Schmoll HJ
Br J Cancer; 2009 Oct; 101(8):1241-7. PubMed ID: 19773753
[TBL] [Abstract][Full Text] [Related]
14. Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells.
Gan PP; McCarroll JA; Byrne FL; Garner J; Kavallaris M
PLoS One; 2011; 6(6):e21717. PubMed ID: 21738778
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of GINS2 inhibits proliferation and promotes apoptosis through the p53/GADD45A pathway in non-small-cell lung cancer.
Chi F; Wang Z; Li Y; Chang N
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32181475
[TBL] [Abstract][Full Text] [Related]
16. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
Kamath K; Jordan MA
Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
[TBL] [Abstract][Full Text] [Related]
17. An anthraquinone derivative from Luffa acutangula induces apoptosis in human lung cancer cell line NCI-H460 through p53-dependent pathway.
Vanajothi R; Srinivasan P
J Recept Signal Transduct Res; 2016; 36(3):292-302. PubMed ID: 26585176
[TBL] [Abstract][Full Text] [Related]
18. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
Chen JG; Horwitz SB
Cancer Res; 2002 Apr; 62(7):1935-8. PubMed ID: 11929805
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.
Schmid P; Kiewe P; Possinger K; Korfel A; Lindemann S; Giurescu M; Reif S; Wiesinger H; Thiel E; Kühnhardt D
Ann Oncol; 2010 Mar; 21(3):633-639. PubMed ID: 19880436
[TBL] [Abstract][Full Text] [Related]
20. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
Heigener DF; von Pawel J; Eschbach C; Brune A; Schmittel A; Schmelter T; Reck M; Fischer JR
Lung Cancer; 2013 Jun; 80(3):319-25. PubMed ID: 23522488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
